XBIO Xenetic Biosciences: חובות לטווח קצר של החברה

Xenetic Biosciences (XBIO) develops anti-tumor delivery systems, generating revenue through long-term licenses and royalties. Patents create a defensive moat for the business, although success depends on FDA approval. The price action of securities with the 0.00 metric is shown below. The asset is not subject to inflation, as quotes are determined exclusively by medical test results and stable demand for therapy.

This indicator measures obligations with a maturity of up to one year, determining short-term solvency and the risk of liquidity loss. The trend in current liabilities reflects the financial stability of Xenetic Biosciences (XBIO), as a high dependence on external CROs and outsourced clinical trials requires a constant availability of free cash to fund contracts.